Vancouver, Canada – October 22, 2025 — Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that AiArthritis has launched a new patient education feature focused on the 14-3-3eta blood test in rheumatoid arthritis (RA). AiArthritis is a global patient advocacy organization dedicated to improving the lives of people with autoimmune and autoinflammatory arthritis.
In addition to publishing a dedicated blog, AiArthritis has also updated its RA diagnosis page to include information on 14-3-3eta, giving patients more resources when learning about diagnostic options. Together, these new materials provide clear, accessible education to support more informed decision-making across the RA care pathway.
Timely and accurate information is critical in RA, where delayed diagnosis can lead to preventable joint damage and reduced quality of life. AiArthritis’ new content expands patient education on how biomarker testing, including 14-3-3eta, can complement traditional tools such as RF, anti-CCP, CRP, imaging, and clinical evaluation.
The resources explain how 14-3-3eta testing can help to:
- Detect RA earlier, including in patients who test negative for rheumatoid factor (RF) and anti-CCP (seronegative RA)
- Identify patients at higher risk of joint damage, informing treatment escalation and follow-up
- Track response to treatment and complement CRP in monitoring disease progression
By adding 14-3-3eta to its RA diagnosis page and spotlighting the marker in a dedicated blog, AiArthritis is helping ensure that patients and their healthcare providers are aware of the latest innovations that can reduce uncertainty, enable earlier intervention, and improve outcomes.
Augurex remains committed to advancing biomarker-driven solutions and supporting education that empowers both patients and providers.
- Read the AiArthritis biomarker blog → AiArthritis blog
- See the updated RA diagnosis page → RA diagnosis page
- Learn more about 14-3-3eta testing → Augurex RA page
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat® in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com